HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)

Market Cap	10.55B +24.9%
Revenue (ttm)	2.12B -11.5%
Net Income	411.58M +71.0%
EPS	0.18 +74.4%
Shares Out	2.23B
PE Ratio	25.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	485,384,066
Open	4.430
Previous Close	4.300
Day's Range	4.390 - 4.730
52-Week Range	2.370 - 5.100
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHE:002437

HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 2,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002437

Financial Performance

In 2025, SHE:002437's revenue was 2.14 billion, a decrease of -12.51% compared to the previous year's 2.44 billion. Earnings were 376.91 million, an increase of 61.93%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error